Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biocytogen Forms ADC Partnership with Myriex, a Cytotoxic Payload Company

publication date: Sep 7, 2023

Beijing Biocytogen Pharma struck a deal to discover innovative antibody candidates for use with original cytotoxic payloads developed by Myricx Bio, a UK biotech focused on novel selective cytotoxic payloads for antibody drug conjugates. Myricx will provide its proprietary linker and payload while Biocytogen will conjugate them with its RenMice®-derived antibodies to make ADCs. Using its CRO services, Biocytogen will conduct feasibility tests for the ADCs. Myricx has an option to acquire the ADCs and will be responsible for further development and commercialization. Biocytogen will receive an upfront payment and be eligible for milestones and single-digit royalties. More details....

Stock Symbol: (HK: 02315)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital